University of Leicester
Browse
Bifunctional HDAC Therapeutics One Drug to Rule.pdf (2.57 MB)

Bifunctional HDAC therapeutics: One drug to rule them all?

Download (2.57 MB)
journal contribution
posted on 2020-11-20, 10:21 authored by JP Smalley, SM Cowley, JT Hodgkinson
Histone deacetylase (HDAC) enzymes play crucial roles in epigenetic gene expression and are an attractive therapeutic target. Five HDAC inhibitors have been approved for cancer treatment to date, however, clinical applications have been limited due to poor single-agent drug efficacy and side effects associated with a lack of HDAC isoform or complex selectivity. An emerging strategy aiming to address these limitations is the development of bifunctional HDAC therapeutics—single molecules comprising a HDAC inhibitor conjugated to another specificity targeting moiety. This review summarises the recent advancements in novel types of dual-targeting HDAC modulators, including proteolysis-targeting chimeras (PROTACs), with a focus on HDAC isoform and complex selectivity, and the future potential of such bifunctional molecules in achieving enhanced drug efficacy and therapeutic benefits in treating disease.

History

Citation

Molecules 2020, 25(19), 4394; https://doi.org/10.3390/molecules25194394

Author affiliation

Leicester Institute of Structural and Chemical Biology, School of Chemistry

Version

  • VoR (Version of Record)

Published in

Molecules

Volume

25

Issue

19

Pagination

4394 - 4394

Publisher

MDPI AG

issn

1420-3049

eissn

1420-3049

Acceptance date

2020-09-23

Copyright date

2020

Available date

2020-09-24

Spatial coverage

Switzerland

Language

English

Usage metrics

    University of Leicester Publications

    Categories

    Licence

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC